dexcom g6 rt cgm  (Dexcom Inc)

Journal: Reviews in Endocrine & Metabolic Disorders

Article Title: Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications

doi: 10.1007/s11154-024-09903-y

Figure Lengend Snippet: Rt-CGM/FGM in CH: population features, devices and study design

Article Snippet: Worth et al. 2023 [ ] , n.9 CH , 2.1-17.7y , Rt-CGM , Decom G6 (Dexcom), blinded and not-blinded , 12weeks (0–4 w = blinded, 4–8 w = not-blinded, at week 8 Hypo-Cheat output, 8–12 w = blinded, 12 weeks expert review) , Observational (pilot study) , Poor.

Techniques: Biomarker Discovery, Control

Journal: Advances in Therapy

Article Title: Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy

doi: 10.1007/s12325-024-02851-8

Figure Lengend Snippet:

Article Snippet: The findings in this study indicate that significant reductions in diabetes-related HCRU were associated with initiation of Dexcom G6 RT-CGM in this population.

Techniques:

Journal: Advances in Therapy

Article Title: Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy

doi: 10.1007/s12325-024-02851-8

Figure Lengend Snippet: Prevalence of diabetes-related emergency department (ED) or inpatient encounters and associated costs among individuals with T2D using intensive insulin therapy

Article Snippet: The cohort consisted of commercially insured, CGM-naïve individuals with T2D who initiated Dexcom G6 RT-CGM system between August 1, 2018, and March 31, 2021.

Techniques:

Journal: Advances in Therapy

Article Title: Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy

doi: 10.1007/s12325-024-02851-8

Figure Lengend Snippet:

Article Snippet: The cohort consisted of commercially insured, CGM-naïve individuals with T2D who initiated Dexcom G6 RT-CGM system between August 1, 2018, and March 31, 2021.

Techniques: